Buprenorphine transdermal patch
Sponsors
Purdue Pharma LP, Mundipharma AB, Mundipharma Pte Ltd., Mundipharma Pharmaceuticals Sdn. Bhd., Mundipharma (China) Pharmaceutical Co. Ltd
Conditions
AnalgesicArthroscopyBack PainBack Pain Lower Back ChronicBuprenorphineChronic Non-malignant PainChronic Nonmalignant PainChronic Pain
Phase 1
The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers
CompletedNCT01148537
Start: 2004-07-31End: 2004-12-31Updated: 2012-09-03
Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods
CompletedNCT01259102
Start: 2000-11-30End: 2001-03-31Updated: 2012-09-03
Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole
CompletedNCT01259115
Start: 2002-10-31End: 2003-06-30Updated: 2014-05-19
The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers
CompletedNCT01999114
Start: 2012-03-31End: 2012-10-31Updated: 2018-11-05
Buprenorphine Transdermal Patches Pharmacokinetic Study
NCT03975010
Start: 2019-05-13End: 2020-03-31Target: 45Updated: 2019-06-05
Phase 2
Phase 3
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain
CompletedNCT00312195
Start: 2001-03-31End: 2001-07-31Updated: 2012-09-10
Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain
CompletedNCT00312572
Start: 2003-06-30End: 2004-07-31Updated: 2012-09-03
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
CompletedNCT00313846
Start: 2003-04-30End: 2004-06-30Updated: 2012-09-03
The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.
CompletedNCT00315445
Start: 1997-12-31End: 1998-05-31Updated: 2012-09-03
Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.
TerminatedNCT00315458
Start: 2003-12-31End: 2005-03-31Updated: 2012-09-03
Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.
TerminatedNCT00320801
Start: 2004-01-31End: 2005-03-31Updated: 2012-09-03
Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015
TerminatedNCT01125917
Start: 2004-06-30End: 2008-01-31Updated: 2012-09-03
Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase
TerminatedNCT01135524
Start: 2004-04-30End: 2005-08-31Updated: 2012-09-10
Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
CompletedNCT01141283
Start: 2003-04-30End: 2004-07-31Updated: 2012-09-03
Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study
CompletedNCT01151098
Start: 2001-04-30End: 2002-02-28Updated: 2012-09-10
Phase 4
Norspan Efficacy and Safety Among Elderly Subjects
CompletedNCT01276431
Start: 2011-03-31End: 2012-08-31Updated: 2014-02-06
Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
CompletedNCT01961271
Start: 2013-06-30End: 2015-01-31Updated: 2016-09-23
Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity
CompletedNCT02519387
Start: 2013-07-31End: 2015-01-31Updated: 2016-07-20
Comparative Efficacy of Buprenorphine Transdermal Patch Versus Tramadol in Postoperative Analgesia for Shoulder Arthroscopy
Active, not recruitingNCT06742554
Start: 2024-12-01End: 2025-04-30Target: 70Updated: 2024-12-20